Shalender Bhasin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shalender Bhasin has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
A. B. Singh
6 shared publications- R. Jasuja
Charles Drew University and RCMI Molecular Medicine and Stem Cell Core, Los Angeles, CA
6 shared publications Thomas W. Storer
Division of Endocrinology, Metabolism, and Molecular Medicine, Charles R. Drew University of Medicine and Science (S.B., L.W., A.B.S., R.P.M., M.L., I.S.-H., C.D., J.D., L.M., T.W.S.), Los Angeles, California 90059 3 Laboratory for Exercise Science, El Camino College (T.W.S.), Torrance, California 90502
5 shared publicationsC. Dzekov
4 shared publicationsC. Padero
4 shared publicationsIndrani Sinha-Hikim
Division of Endocrinology, Metabolism, and Molecular Medicine, Charles R. Drew University of Medicine and Science (S.B., L.W., A.B.S., R.P.M., M.L., I.S.-H., C.D., J.D., L.M., T.W.S.), Los Angeles, California 90059
4 shared publications
Latest Publications
- 30 November 2012
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 108 (2) , 750-759
Numerical framework to model temporally resolved multi-stage dynamic systems
- 30 November 2012
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 108 (2) , 750-759
Numerical framework to model temporally resolved multi-stage dynamic systems
- 1 June 2010
- Published by The Endocrine Society
- p. P2-453
Durability of the Effects of Testosterone and Growth Hormone Supplementation in Older Community Dwelling Men: The HORMA Trial.
Testosterone (T) and rhGH are potential function promoting treatments (Rx) for aging-associated loss of muscle mass and performance, but the durability of beneficial and adverse effects (AEs) after stopping Rx is unknown.
- 1 June 2010
- Published by The Endocrine Society
- p. P2-453
Durability of the Effects of Testosterone and Growth Hormone Supplementation in Older Community Dwelling Men: The HORMA Trial.
Testosterone (T) and rhGH are potential function promoting treatments (Rx) for aging-associated loss of muscle mass and performance, but the durability of beneficial and adverse effects (AEs) after stopping Rx is unknown.
- 1 June 2010
- Published by The Endocrine Society
- p. S19-6
5-α Reduction of Testosterone to Dihydrotestosterone Is Not Required in Mediating Its Effects on Muscle and Sexual Function.
Article published by the Endocrine Society Article published by the Endocrine Society
- 1 June 2010
- Published by The Endocrine Society
- p. S19-6
5-α Reduction of Testosterone to Dihydrotestosterone Is Not Required in Mediating Its Effects on Muscle and Sexual Function.
Article published by the Endocrine Society Article published by the Endocrine Society
- 1 January 2007
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 55 (1) , S86
MYOSTATIN OVEREXPRESSION REDUCES HEART MASS IN THE MOUSE BUT DOES NOT AFFECT CARDIAC FUNCTION.
- 1 January 2007
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 55 (1) , S86
MYOSTATIN OVEREXPRESSION REDUCES HEART MASS IN THE MOUSE BUT DOES NOT AFFECT CARDIAC FUNCTION.
- 1 January 2007
- Published by BMJ in Journal of Investigative Medicine
- Vol. 55 (1) , S86
TESTOSTERONE REGULATION OF MUSCLE MASS: IN VITRO AND IN VIVO ROLE OF FOLLISTATIN.
- 1 January 2007
- Published by BMJ in Journal of Investigative Medicine
- Vol. 55 (1) , S86
TESTOSTERONE REGULATION OF MUSCLE MASS: IN VITRO AND IN VIVO ROLE OF FOLLISTATIN.
- 1 January 2006
- Published by BMJ in Journal of Investigative Medicine
- Vol. 54 (1) , S152.1-S152
421 DIFFERENCES IN SUBJECTIVE AND OBJECTIVE SEXUAL FUNCTION BETWEEN HISPANIC AND NON-HISPANIC WOMEN.
- 1 January 2006
- Published by BMJ in Journal of Investigative Medicine
- Vol. 54 (1) , S152.1-S152
421 DIFFERENCES IN SUBJECTIVE AND OBJECTIVE SEXUAL FUNCTION BETWEEN HISPANIC AND NON-HISPANIC WOMEN.
- 1 January 2006
- Published by BMJ in Journal of Investigative Medicine
- Vol. 54 (1) , S96.1-S96
95 DIHYDROTESTOSTERONE-INDUCED CONFORMATIONAL PERTURBATIONS IN ANDROGEN RECEPTOR: KINETIC AND THERMODYNAMIC INSIGHTS.
- 1 January 2006
- Published by BMJ in Journal of Investigative Medicine
- Vol. 54 (1) , S96.1-S96
95 DIHYDROTESTOSTERONE-INDUCED CONFORMATIONAL PERTURBATIONS IN ANDROGEN RECEPTOR: KINETIC AND THERMODYNAMIC INSIGHTS.
- 1 January 2006
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 54 (1) , S96.5-S96
99 TESTOSTERONE MODULATES TRANSFORMING GROWTH FACTOR β SIGNALING PATHWAY GENES IN MESENCHYMAL PLURIPOTENT C3H 10T1/2 STEM CELLS: IMPLICATIONS IN REGULATION OF BODY COMPOSITION.
Transforming growth factor β (TGFβ) family members play important roles in directing the fate of mesenchymal stem cells. We have previously demonstrated that testosterone promotes the commitment of pluripotent C3H 10T1/2 cells to promote myogenesis and inhibit adipogenesis via androgen receptor (AR)-dependent pathway. The objective of our current study is to identify possible target genes in TGF-β signaling pathway which may be regulated by androgens. Our microarray analysis in C3H 10T1/2 cells treated with or without testosterone (100 nM) for either 3 hours (early) or 4 days (late) suggest that T significantly up-regulates several genes, including FKBP1B, a regulator of type I receptor, follistatin (Fst, which binds and inhibits myostatin (Mst), a well-known inhibitor of muscle mass, Smad 7, BMP10, RunX1, GDF1, and GDF3, whereas it down-regulates Smad2/3 among other genes. In parallel studies we assessed the effects of T treatment on myostatin (a positive regulator of TGF-β, also termed GDF8) induced genes. Our data suggest that T up-regulates Fst, RunX1, Smad7, and several other genes in these cells pretreated with Mst. We confirmed these findings by real-time quantitative PCR analysis. Our immunocytochemical and Western blot analysis data suggest that testosterone inhibits Smad 2/3 phosphorylation induced by recombinant Mst and TGF-β and up-regulates Smad7, an inhibitory Smad in the TGF-β signaling pathway. Combined with our previous findings that T activates AR/β-catenin/TCF4 pathway to up-regulate Fst (Singh et al, 2005, Endocrinology), a known Wnt downstream target gene and inhibitor of TGF-β signaling, with a putative TCF4 binding site in the promoter region, our current data suggest that T may mediate its inhibitory action on the TGF-β pathway to regulate the fate of pluripotent stem cells. Our findings may provide a rationale for targeting key components of TGF-β family pathway genes that are responsible for regulating muscle, fat, and bone differentiation of pluripotent stem cells and thereby regulate body composition.
- 1 January 2006
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 54 (1) , S96.5-S96
99 TESTOSTERONE MODULATES TRANSFORMING GROWTH FACTOR β SIGNALING PATHWAY GENES IN MESENCHYMAL PLURIPOTENT C3H 10T1/2 STEM CELLS: IMPLICATIONS IN REGULATION OF BODY COMPOSITION.
Transforming growth factor β (TGFβ) family members play important roles in directing the fate of mesenchymal stem cells. We have previously demonstrated that testosterone promotes the commitment of pluripotent C3H 10T1/2 cells to promote myogenesis and inhibit adipogenesis via androgen receptor (AR)-dependent pathway. The objective of our current study is to identify possible target genes in TGF-β signaling pathway which may be regulated by androgens. Our microarray analysis in C3H 10T1/2 cells treated with or without testosterone (100 nM) for either 3 hours (early) or 4 days (late) suggest that T significantly up-regulates several genes, including FKBP1B, a regulator of type I receptor, follistatin (Fst, which binds and inhibits myostatin (Mst), a well-known inhibitor of muscle mass, Smad 7, BMP10, RunX1, GDF1, and GDF3, whereas it down-regulates Smad2/3 among other genes. In parallel studies we assessed the effects of T treatment on myostatin (a positive regulator of TGF-β, also termed GDF8) induced genes. Our data suggest that T up-regulates Fst, RunX1, Smad7, and several other genes in these cells pretreated with Mst. We confirmed these findings by real-time quantitative PCR analysis. Our immunocytochemical and Western blot analysis data suggest that testosterone inhibits Smad 2/3 phosphorylation induced by recombinant Mst and TGF-β and up-regulates Smad7, an inhibitory Smad in the TGF-β signaling pathway. Combined with our previous findings that T activates AR/β-catenin/TCF4 pathway to up-regulate Fst (Singh et al, 2005, Endocrinology), a known Wnt downstream target gene and inhibitor of TGF-β signaling, with a putative TCF4 binding site in the promoter region, our current data suggest that T may mediate its inhibitory action on the TGF-β pathway to regulate the fate of pluripotent stem cells. Our findings may provide a rationale for targeting key components of TGF-β family pathway genes that are responsible for regulating muscle, fat, and bone differentiation of pluripotent stem cells and thereby regulate body composition.
- Top Cited PapersOpen Access
- 1 February 2005
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (2) , 678-688
Older Men Are as Responsive as Young Men to the Anabolic Effects of Graded Doses of Testosterone on the Skeletal Muscle
Although testosterone levels and muscle mass decline with age, many older men have serum testosterone level in the normal range, leading to speculation about whether older men are less sensitive to testosterone. We determined the responsiveness of androgen-dependent outcomes to graded testosterone doses in older men and compared it to that in young men. The participants in this randomized, double-blind trial were 60 ambulatory, healthy, older men, 60–75 yr of age, who had normal serum testosterone levels. Their responses to graded doses of testosterone were compared with previous data in 61 men, 19–35 yr old. The participants received a long-acting GnRH agonist to suppress endogenous testosterone production and 25, 50, 125, 300, or 600 mg testosterone enanthate weekly for 20 wk. Fat-free mass, fat mass, muscle strength, sexual function, mood, visuospatial cognition, hormone levels, and safety measures were evaluated before, during, and after treatment. Of 60 older men who were randomized, 52 completed the study. After adjusting for testosterone dose, changes in serum total testosterone (change, −6.8, −1.9, +16.1, +49.5, and +101.9 nmol/liter at 25, 50, 125, 300, and 600 mg/wk, respectively) and hemoglobin (change, −3.6, +9.9, +20.9, +12.6, and +29.4 g/liter at 25, 50, 125, 300, and 600 mg/wk, respectively) levels were dose-related in older men and significantly greater in older men than young men (each P < 0.0001). The changes in FFM (−0.3, +1.7, +4.2, +5.6, and +7.3 kg, respectively, in five ascending dose groups) and muscle strength in older men were correlated with testosterone dose and concentrations and were not significantly different in young and older men. Changes in fat mass correlated inversely with testosterone dose (r = −0.54; P < 0.001) and were significantly different in young vs. older men (P < 0.0001); young men receiving 25- and 50-mg doses gained more fat mass than older men (P < 0.0001). Mood and visuospatial cognition did not change significantly in either group. Frequency of hematocrit greater than 54%, leg edema, and prostate events were numerically higher in older men than in young men. Older men are as responsive as young men to testosterone’s anabolic effects; however, older men have lower testosterone clearance rates, higher increments in hemoglobin, and a higher frequency of adverse effects. Although substantial gains in muscle mass and strength can be realized in older men with supraphysiological testosterone doses, these high doses are associated with a high frequency of adverse effects. The best trade-off was achieved with a testosterone dose (125 mg) that was associated with high normal testosterone levels, low frequency of adverse events, and significant gains in fat-free mass and muscle strength.
- 1 February 2005
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (2) , 678-688
Top Cited PapersOpen AccessOlder Men Are as Responsive as Young Men to the Anabolic Effects of Graded Doses of Testosterone on the Skeletal Muscle
Although testosterone levels and muscle mass decline with age, many older men have serum testosterone level in the normal range, leading to speculation about whether older men are less sensitive to testosterone. We determined the responsiveness of androgen-dependent outcomes to graded testosterone doses in older men and compared it to that in young men. The participants in this randomized, double-blind trial were 60 ambulatory, healthy, older men, 60–75 yr of age, who had normal serum testosterone levels. Their responses to graded doses of testosterone were compared with previous data in 61 men, 19–35 yr old. The participants received a long-acting GnRH agonist to suppress endogenous testosterone production and 25, 50, 125, 300, or 600 mg testosterone enanthate weekly for 20 wk. Fat-free mass, fat mass, muscle strength, sexual function, mood, visuospatial cognition, hormone levels, and safety measures were evaluated before, during, and after treatment. Of 60 older men who were randomized, 52 completed the study. After adjusting for testosterone dose, changes in serum total testosterone (change, −6.8, −1.9, +16.1, +49.5, and +101.9 nmol/liter at 25, 50, 125, 300, and 600 mg/wk, respectively) and hemoglobin (change, −3.6, +9.9, +20.9, +12.6, and +29.4 g/liter at 25, 50, 125, 300, and 600 mg/wk, respectively) levels were dose-related in older men and significantly greater in older men than young men (each P < 0.0001). The changes in FFM (−0.3, +1.7, +4.2, +5.6, and +7.3 kg, respectively, in five ascending dose groups) and muscle strength in older men were correlated with testosterone dose and concentrations and were not significantly different in young and older men. Changes in fat mass correlated inversely with testosterone dose (r = −0.54; P < 0.001) and were significantly different in young vs. older men (P < 0.0001); young men receiving 25- and 50-mg doses gained more fat mass than older men (P < 0.0001). Mood and visuospatial cognition did not change significantly in either group. Frequency of hematocrit greater than 54%, leg edema, and prostate events were numerically higher in older men than in young men. Older men are as responsive as young men to testosterone’s anabolic effects; however, older men have lower testosterone clearance rates, higher increments in hemoglobin, and a higher frequency of adverse effects. Although substantial gains in muscle mass and strength can be realized in older men with supraphysiological testosterone doses, these high doses are associated with a high frequency of adverse effects. The best trade-off was achieved with a testosterone dose (125 mg) that was associated with high normal testosterone levels, low frequency of adverse events, and significant gains in fat-free mass and muscle strength.